{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:40:17Z","timestamp":1791186017457,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,7,21]],"date-time":"2011-07-21T00:00:00Z","timestamp":1311206400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s00198-011-1691-1","type":"journal-article","created":{"date-parts":[[2011,7,20]],"date-time":"2011-07-20T10:38:12Z","timestamp":1311158292000},"page":"351-363","source":"Crossref","is-referenced-by-count":136,"title":["Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study"],"prefix":"10.1007","volume":"23","author":[{"name":"for the Bazedoxifene Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. L.","family":"Silverman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. A.","family":"Chines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. L.","family":"Kendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. W. C.","family":"Kung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. S.","family":"Teglbj\u00e6rg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Felsenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Mairon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. D.","family":"Constantine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. D.","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,7,21]]},"reference":[{"key":"1691_CR1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/01.blo.0000200248.34876.fe","volume":"443","author":"OS Atik","year":"2006","unstructured":"Atik OS, Gunal I, Korkusuz F (2006) Burden of osteoporosis. Clin Orthop Relat Res 443:19\u201324","journal-title":"Clin Orthop Relat Res"},{"key":"1691_CR2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1503\/cmaj.081720","volume":"181","author":"G Ioannidis","year":"2009","unstructured":"Ioannidis G, Papaioannou A, Hopman WM, Khtar-Danesh N, Anastassiades T, Pickard L, Kennedy CC, Prior JC, Olszynski WP, Davison KS, Goltzman D, Thabane L, Gafni A, Papadimitropoulos EA, Brown JP, Josse RG, Hanley DA, Adachi JD (2009) Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ 181:265\u2013271","journal-title":"CMAJ"},{"key":"1691_CR3","unstructured":"National Osteoporosis Foundation (2010) Fast facts on osteoporosis. http:\/\/www.nof.org\/osteoporosis\/diseasefacts.htm . Accessed 4 August 2010"},{"key":"1691_CR4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/gme.0b013e3181c617e6","volume":"17","author":"North American Menopause Society","year":"2010","unstructured":"North American Menopause Society (2010) Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 17:25\u201354","journal-title":"Menopause"},{"key":"1691_CR5","first-page":"1551","volume":"34","author":"F Salaffi","year":"2007","unstructured":"Salaffi F, Cimmino MA, Malavolta N, Carotti M, Di ML, Scendoni P, Grassi W (2007) The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study. J Rheumatol 34:1551\u20131560","journal-title":"J Rheumatol"},{"key":"1691_CR6","first-page":"140","volume":"34","author":"SL Silverman","year":"2007","unstructured":"Silverman SL, Shen W, Minshall ME, Xie S, Moses KH (2007) Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and\/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. J Rheumatol 34:140\u2013144","journal-title":"J Rheumatol"},{"key":"1691_CR7","first-page":"1","volume":"16","author":"J Ostermiller","year":"2008","unstructured":"Ostermiller J, Hatz J (2008) Osteoporosis breaks bones and budgets. NCSL Legisbrief 16:1\u20132","journal-title":"NCSL Legisbrief"},{"key":"1691_CR8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.061113","volume":"22","author":"R Burge","year":"2007","unstructured":"Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005\u20132025. J Bone Miner Res 22:465\u2013475","journal-title":"J Bone Miner Res"},{"key":"1691_CR9","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s00198-010-1208-3","volume":"21","author":"PD Miller","year":"2010","unstructured":"Miller PD, Derman RJ (2010) What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis? Osteoporos Int 21:1793\u20131802","journal-title":"Osteoporos Int"},{"key":"1691_CR10","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1089\/jwh.2008.1086","volume":"18","author":"EM Lewiecki","year":"2009","unstructured":"Lewiecki EM (2009) Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis. J Womens Health (Larchmt) 18:1615\u20131626","journal-title":"J Womens Health (Larchmt)"},{"key":"1691_CR11","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1210\/en.2005-0030","volume":"146","author":"BS Komm","year":"2005","unstructured":"Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lyttle CR (2005) Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 146:3999\u20134008","journal-title":"Endocrinology"},{"key":"1691_CR12","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1359\/jbmr.071206","volume":"23","author":"PD Miller","year":"2008","unstructured":"Miller PD, Chines AA, Christiansen C, Hoeck HC, Kendler DL, Lewiecki EM, Woodson G, Levine AB, Constantine G, Delmas PD (2008) Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 23:525\u2013535","journal-title":"J Bone Miner Res"},{"key":"1691_CR13","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1359\/jbmr.080710","volume":"23","author":"SL Silverman","year":"2008","unstructured":"Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA (2008) Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 23:1923\u20131934","journal-title":"J Bone Miner Res"},{"key":"1691_CR14","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bone.2009.02.014","volume":"44","author":"JA Kanis","year":"2009","unstructured":"Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 44:1049\u20131054","journal-title":"Bone"},{"key":"1691_CR15","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/jbmr.5650110716","volume":"11","author":"HK Genant","year":"1996","unstructured":"Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D, Cummings SR, for the Study of Osteoporotic Fractures Research Group (1996) Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. J Bone Miner Res 11:984\u2013996","journal-title":"J Bone Miner Res"},{"key":"1691_CR16","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"CHI Chesnut","year":"2004","unstructured":"Chesnut CHI, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241\u20131249","journal-title":"J Bone Miner Res"},{"key":"1691_CR17","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1359\/jbmr.1999.14.5.821","volume":"14","author":"DM Black","year":"1999","unstructured":"Black DM, Arden NK, Palermo L, Pearson J, Cummings SR, for the Study of Osteoporotic Fractures Research Group (1999) Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. J Bone Miner Res 14:821\u2013828","journal-title":"J Bone Miner Res"},{"issue":"2","key":"1691_CR18","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00198-010-1302-6","volume":"22","author":"TJ Villiers de","year":"2011","unstructured":"de Villiers TJ, Chines AA, Palacios S, Lips P, Sawicki AZ, Levine AB, Codreanu C, Kelepouris N, Brown JP (2011) Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 22(2):567\u2013576","journal-title":"Osteoporos Int"},{"key":"1691_CR19","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1210\/jc.87.8.3609","volume":"87","author":"PD Delmas","year":"2002","unstructured":"Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R (2002) Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609\u20133617","journal-title":"J Clin Endocrinol Metab"},{"key":"1691_CR20","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJMoa0808692","volume":"362","author":"SR Cummings","year":"2010","unstructured":"Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J, Armstrong RA, Thompson DD, Powles T, Zanchetta J, Kendler D, Neven P, Eastell R (2010) Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 362:686\u2013696","journal-title":"N Engl J Med"},{"key":"1691_CR21","unstructured":"Pfizer Inc (2008) FABLYN\u00ae (lasofoxifene tartrate) 0.5\u00a0mg tablets. NDA 22\u2013242. Reproductive Health Drugs Advisory Committee Briefing Document, 08 September 2008. http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/08\/briefing\/2008-4381b1-02-Pfizer.pdf . Accessed 10 December 2009"},{"key":"1691_CR22","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMra053077","volume":"354","author":"E Seeman","year":"2006","unstructured":"Seeman E, Delmas PD (2006) Bone quality\u2014the material and structural basis of bone strength and fragility. N Engl J Med 354:2250\u20132261","journal-title":"N Engl J Med"},{"key":"1691_CR23","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1359\/jbmr.2002.17.7.1139","volume":"17","author":"B Borah","year":"2002","unstructured":"Borah B, Dufresne TE, Chmielewski PA, Gross GJ, Prenger MC, Phipps RJ (2002) Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J Bone Miner Res 17:1139\u20131147","journal-title":"J Bone Miner Res"},{"key":"1691_CR24","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","volume":"18","author":"R Eastell","year":"2003","unstructured":"Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051\u20131056","journal-title":"J Bone Miner Res"},{"key":"1691_CR25","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","volume":"19","author":"DC Bauer","year":"2004","unstructured":"Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19:1250\u20131258","journal-title":"J Bone Miner Res"},{"key":"1691_CR26","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jnci\/djh319","volume":"96","author":"S Martino","year":"2004","unstructured":"Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR (2004) Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96:1751\u20131761","journal-title":"J Natl Cancer Inst"},{"key":"1691_CR27","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR, for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637\u2013645","journal-title":"JAMA"},{"key":"1691_CR28","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","volume":"281","author":"SR Cummings","year":"1999","unstructured":"Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189\u20132197","journal-title":"JAMA"},{"key":"1691_CR29","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/01.AOG.0000137349.79204.b8","volume":"104","author":"D Grady","year":"2004","unstructured":"Grady D, Ettinger B, Moscarelli E, Plouffe L Jr, Sarkar S, Ciaccia A, Cummings S (2004) Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol 104:837\u2013844","journal-title":"Obstet Gynecol"},{"key":"1691_CR30","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/gme.0b013e3181a818db","volume":"16","author":"DF Archer","year":"2009","unstructured":"Archer DF, Pinkerton JV, Utian WH, Menegoci JC, de Villiers TJ, Yuen CK, Levine AB, Chines AA, Constantine GD (2009) Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause 16:1109\u20131115","journal-title":"Menopause"},{"key":"1691_CR31","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/gme.0b013e3181a816be","volume":"16","author":"JV Pinkerton","year":"2009","unstructured":"Pinkerton JV, Archer DF, Utian WH, Menegoci JC, Levine AB, Chines AA, Constantine GD (2009) Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. Menopause 16:1102\u20131108","journal-title":"Menopause"},{"key":"1691_CR32","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/gme.0b013e3181a7fb1e","volume":"16","author":"JA Harvey","year":"2009","unstructured":"Harvey JA, Holm MK, Ranganath R, Guse PA, Trott EA, Helzner E (2009) The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis. Menopause 16:1193\u20131196","journal-title":"Menopause"},{"key":"1691_CR33","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1365-2125.2004.02103.x","volume":"57","author":"RV Carlson","year":"2004","unstructured":"Carlson RV, Boyd KM, Webb DJ (2004) The revision of the Declaration of Helsinki: past, present and future. Br J Clin Pharmacol 57:695\u2013713","journal-title":"Br J Clin Pharmacol"},{"key":"1691_CR34","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jc.85.11.4118","volume":"85","author":"DM Black","year":"2000","unstructured":"Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR, for the FIT Research Group (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 85:4118\u20134124","journal-title":"J Clin Endocrinol Metab"},{"key":"1691_CR35","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344\u20131352","journal-title":"JAMA"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-011-1691-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-011-1691-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-011-1691-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T15:08:39Z","timestamp":1558624119000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-011-1691-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,21]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["1691"],"URL":"https:\/\/doi.org\/10.1007\/s00198-011-1691-1","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,21]]}}}